Orrstown Financial Services Inc. Has $381,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Orrstown Financial Services Inc. raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 35.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 947 shares of the pharmaceutical company’s stock after buying an additional 248 shares during the quarter. Orrstown Financial Services Inc.’s holdings in Vertex Pharmaceuticals were worth $381,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of VRTX. Driehaus Capital Management LLC increased its stake in Vertex Pharmaceuticals by 25.2% during the second quarter. Driehaus Capital Management LLC now owns 1,169 shares of the pharmaceutical company’s stock valued at $548,000 after acquiring an additional 235 shares during the period. NewEdge Advisors LLC grew its holdings in shares of Vertex Pharmaceuticals by 5.5% during the 2nd quarter. NewEdge Advisors LLC now owns 13,632 shares of the pharmaceutical company’s stock worth $6,390,000 after purchasing an additional 709 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Vertex Pharmaceuticals by 92.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 15,942 shares of the pharmaceutical company’s stock valued at $7,471,000 after purchasing an additional 7,647 shares during the period. Regal Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 3.7% in the second quarter. Regal Investment Advisors LLC now owns 2,056 shares of the pharmaceutical company’s stock valued at $963,000 after purchasing an additional 73 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its stake in Vertex Pharmaceuticals by 10.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 10,389 shares of the pharmaceutical company’s stock worth $4,870,000 after buying an additional 946 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ VRTX traded down $1.19 during mid-day trading on Wednesday, reaching $439.49. 147,467 shares of the company’s stock were exchanged, compared to its average volume of 1,440,316. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $434.75 and a 200 day simple moving average of $463.64. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a market capitalization of $113.18 billion, a price-to-earnings ratio of -220.70, a PEG ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the business posted $3.67 earnings per share. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Scotiabank upped their price target on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research report on Monday, December 23rd. HC Wainwright dropped their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Finally, BMO Capital Markets lowered their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $494.76.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.